ArticleBMC public health2026
Real-world impact of NVX-CoV2373 COVID-19 vaccine in immunocompromised individuals in South Korea.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNVX-CoV2373 is a nanoparticle, protein-based COVID-19 vaccine. Individuals who are immunocompromised (IIC) are at high risk for infection and severe disease; however, real-world NVX-CoV2373 impact data in IIC are limited.
methodsThe objective of this study was to assess whether NVX-CoV2373 reduced the risk of SARS-CoV-2 infection and severe disease in IIC, compared to non-immunocompromised (non-IC) individuals. South Korean IIC aged ≥12 years who received a primary series, third dose, or fourth dose of NVX-CoV2373 were identified in The Korea Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) database. IIC were propensity score matched to non-IC individuals to minimize potential confounding. Outcomes were any and severe SARS-CoV-2 infections, collected in cumulative 30-day risk windows through 180 days post vaccination in primary series and third- and fourth-dose groups. Adjusted hazard ratios (aHRs) measured relative vaccine impact by comparing outcomes between IIC and non-IC individuals across dose groups, overall, and by immunocompromising condition.
resultsA total of 755,727 doses of NVX-CoV2373 were administered from February-December 2022, with 400,435 IIC individuals included in this analysis. Through 180 days, aHRs (95% CI) for any SARS-CoV-2 infection were 1.10 (1.06-1.14), 1.05 (1.01-1.09), and 1.03 (1.02-1.05) for the primary series, third-dose, and fourth-dose groups; severe infection: 0.76 (0.52-1.12), 0.90 (0.53-1.51), and 1.11 (0.87-1.41), respectively. Risk estimates for any infection were relatively consistent across risk windows and among most immunocompromising conditions.
conclusionA similar risk of medically attended SARS-CoV-2 infection between IIC and non-IC was observed with both a homologous primary series and homologous or heterologous third and fourth doses of NVX-CoV2373, as well as across a variety of immunocompromising conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.